Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma

Gaku Takano; Shinichi Esaki; Fumi Goshima; Atsushi Enomoto; Yoshimi Hatano; Haruka Ozaki; Takahiro Watanabe; Yoshitaka Sato; Daisuke Kawakita; Shingo Murakami; Takayuki Murata; Yukihiro Nishiyama; Shinichi Iwasaki; Hiroshi Kimura

doi:10.1016/j.omto.2020.12.007

Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma

Gaku Takano, Shinichi Esaki, Fumi Goshima, Atsushi Enomoto, Yoshimi Hatano, Haruka Ozaki, Takahiro Watanabe, Yoshitaka Sato, Daisuke Kawakita, Shingo Murakami, Takayuki Murata, Yukihiro Nishiyama, Shinichi Iwasaki, Hiroshi Kimura

Virology

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Immune responses can enhance anti-tumor capacity of viruses; therefore, full investigation of oncolytic virotherapy requires use of non-immunodeficient mice. Since no commercial cell lines are available, we established a murine model for oral carcinoma and evaluated oncolytic activity of HF10, naturally attenuated herpes simplex virus, in vitro and in vivo.

Original language	English
Pages (from-to)	220-227
Number of pages	8
Journal	Molecular Therapy Oncolytics
Volume	20
DOIs	https://doi.org/10.1016/j.omto.2020.12.007
Publication status	Published - 26-03-2021

All Science Journal Classification (ASJC) codes

Molecular Medicine
Oncology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.omto.2020.12.007

Cite this

Takano, G., Esaki, S., Goshima, F., Enomoto, A., Hatano, Y., Ozaki, H., Watanabe, T., Sato, Y., Kawakita, D., Murakami, S., Murata, T., Nishiyama, Y., Iwasaki, S., & Kimura, H. (2021). Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma. Molecular Therapy Oncolytics, 20, 220-227. https://doi.org/10.1016/j.omto.2020.12.007

@article{f1d14a5822a24355b1ee36febfc51b56,

title = "Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma",

abstract = "Immune responses can enhance anti-tumor capacity of viruses; therefore, full investigation of oncolytic virotherapy requires use of non-immunodeficient mice. Since no commercial cell lines are available, we established a murine model for oral carcinoma and evaluated oncolytic activity of HF10, naturally attenuated herpes simplex virus, in vitro and in vivo.",

author = "Gaku Takano and Shinichi Esaki and Fumi Goshima and Atsushi Enomoto and Yoshimi Hatano and Haruka Ozaki and Takahiro Watanabe and Yoshitaka Sato and Daisuke Kawakita and Shingo Murakami and Takayuki Murata and Yukihiro Nishiyama and Shinichi Iwasaki and Hiroshi Kimura",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = mar,

day = "26",

doi = "10.1016/j.omto.2020.12.007",

language = "English",

volume = "20",

pages = "220--227",

journal = "Molecular Therapy Oncolytics",

issn = "2372-7705",

publisher = "Cell Press",

}

Takano, G, Esaki, S, Goshima, F, Enomoto, A, Hatano, Y, Ozaki, H, Watanabe, T, Sato, Y, Kawakita, D, Murakami, S, Murata, T, Nishiyama, Y, Iwasaki, S & Kimura, H 2021, 'Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma', Molecular Therapy Oncolytics, vol. 20, pp. 220-227. https://doi.org/10.1016/j.omto.2020.12.007

TY - JOUR

T1 - Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma

AU - Takano, Gaku

AU - Esaki, Shinichi

AU - Goshima, Fumi

AU - Enomoto, Atsushi

AU - Hatano, Yoshimi

AU - Ozaki, Haruka

AU - Watanabe, Takahiro

AU - Sato, Yoshitaka

AU - Kawakita, Daisuke

AU - Murakami, Shingo

AU - Murata, Takayuki

AU - Nishiyama, Yukihiro

AU - Iwasaki, Shinichi

AU - Kimura, Hiroshi

PY - 2021/3/26

Y1 - 2021/3/26

N2 - Immune responses can enhance anti-tumor capacity of viruses; therefore, full investigation of oncolytic virotherapy requires use of non-immunodeficient mice. Since no commercial cell lines are available, we established a murine model for oral carcinoma and evaluated oncolytic activity of HF10, naturally attenuated herpes simplex virus, in vitro and in vivo.

AB - Immune responses can enhance anti-tumor capacity of viruses; therefore, full investigation of oncolytic virotherapy requires use of non-immunodeficient mice. Since no commercial cell lines are available, we established a murine model for oral carcinoma and evaluated oncolytic activity of HF10, naturally attenuated herpes simplex virus, in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=85100380644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100380644&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2020.12.007

DO - 10.1016/j.omto.2020.12.007

M3 - Article

AN - SCOPUS:85100380644

SN - 2372-7705

VL - 20

SP - 220

EP - 227

JO - Molecular Therapy Oncolytics

JF - Molecular Therapy Oncolytics

ER -

Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this